ArticleVirology journal2025
Global trends and insights in interferon therapy for chronic hepatitis B: a bibliometric analysis.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hepatitis B Research in Peru, 1988-2023: Geographic Inequities, Thematic Gaps, and Misalignment with Disease Burden.Pathogens (Basel, Switzerland) · 2026Article
- Clinical burden, disease progression, and management strategies in chronic hepatitis B: implications for public health practice.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic hepatitis B (CHB) is a major global health issue, with interferon (IFN)-based therapy playing a key role in achieving sustained virological response and immune-mediated viral clearance. This study analyzed global research trends, collaborative networks, and emerging priorities in interferon therapy for CHB.
methodsA comprehensive literature search was conducted using the Web of Science Core Collection database. Bibliometric tools, including VOSviewer, CiteSpace, and R-bibliometrix, were employed.
resultsA total of 2,035 studies were analyzed, showing a steady increase in publication activity. China led in research output (891 publications), followed by the USA (172) and Japan (128). Leading institutions included Capital Medical University (211 publications), Fudan University (208), and National Taiwan University (200). Influential journals included Hepatology (h-index = 43), Journal of Hepatology (h-index = 42), and Journal of Viral Hepatitis (h-index = 26). The most prominent authors were Harry L. A. Janssen (TP = 66), Bettina E. Hansen (TP = 39), and Patrick Marcellin (TP = 44). The top three keywords were “therapy” (489 occurrences, total link strength: 2045), “lamivudine” (409 occurrences, total link strength: 2013), and “combination” (243 occurrences, total link strength: 1249). Keywords burst analysis highlighted emerging trends, including “functional cure” (2021–2024), “hbsag loss” (2021–2024), “entecavir” (2019–2024), and “guidelines” (2017–2024).
conclusionsThis bibliometric analysis identifies critical research areas in interferon therapy for CHB, emphasizing advancements in immune mechanisms, therapeutic optimization, and pharmacological innovation. Future research should focus on functional cures, refining treatment guidelines, and integrating innovative strategies to improve clinical outcomes. CLINICAL TRIAL NUMBER: not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.